Our product is called “Toletta®” it is a smart IoT cat litter box that has different layers to separate urine and feces for easier and more convenient clean up. This system also ideal for detecting any abnormalities in your cat’s health that may not be directly noticeable, such as Chronic Kidney Disease. Chronic Kidney Disease is an incurable disease that affects 30% of the whole cat population, it is also tone of the leading causes in cat death. Early symptoms of this disease include an increased urine volume and decreased body weight, which toletta can measure simultaneously. We can also distinguish between various cats via our camera/face recognition technology, and all of your specific cat’s information will be available on our app, which makes our product more convenient for those who lead busy lives like those in the workforce or those who have limited energy to take care of their pet, such as the elderly. Our technology is very unique and innovative to the pet industry because we can help provide early detection, which leads to early treatment to one’s cat, which can prolong their lives so that everyone can live a happy cat life.

Metcela Inc. is a pre-clinical stage biotech startup in Japan. At Metcela, we are developing an innovative, clinically viable and efficacious cell therapy for chronic heart failure using a specific type of fibroblasts found in the heart, called “VCFs” or VCAM-1-positive cardiac fibroblasts. The effects of VCFs in cardiac function have been demonstrated in various animal heart failure models. VCF’s main function is to modify the microenvironment of the infarcted heart to promote survival and proliferation of pre-existing cardiac cells. Unlike many other technologies, our approach is to simply yet truly regenerate the cells that already exist in the heart and help them thrive in a more favorable environment that VCFs create.

　For cell delivery, we have teamed up with a leading catheter manufacturer in Japan to develop a unique injection catheter system which can assist the clinicians to precisely inject VCF to the infarcted areas. Combining the novel characteristics of VCFs and a cutting-edge technology of the precision delivery catheter, we are preparing to initiate an investigator-initiated phase I clinical trial in Japan in early 2021 and later bring the technology to other parts of the world.

Legislation of medical Device traceability will start in the United States in 2020 first and EU and other countries will follow.
Medical professionals pay attention to surgical instrument traceability issue in various countries including Japan as it contributes to patient safety in the end.

Looking at objective of tracability, some Japanese medical professionals misunderstand it as “Identification of indivisual surgical instrument” through barcode but it should include “evaluation of surgical instrument condition (cleaness, functionality and deterioration)” to avoid surgical site infection to the patients. Our goal is realizing quantitaive evaluation system of surgical instrument condition to contribute patient safety.

An uptick in the lifestyle, triggered by jet-speed urbanization and industrialization, at times reveal a few clefts. The change takes people afar from the root which can adversely impact the body. One such is hypertension or high blood pressure. If allowed to persist longer, then it has the potential to lead to much more demanding diseases such as heart failure, stroke, peripheral vascular disease, chronic kidney disease, and others. To counter the disease, anti-hypertensive drugs have been introduced by various drug manufacturers. These drugs are primarily chemicals that can lower high blood pressure or tension and curb chances of contracting myocardial infarction or stroke. Keeping an eye on our blood pressure level is very important for a healthy heart and organ function. If not properly monitored and maintained, high or low blood pressure levels can lead to an assortment of health risks.
With our Smart Intelligent Materials, that show non-radioactive alpha, beta and gamma rays, non-toxic, non-conductive, non-migrating and non-magnetic properties, it can stabilize blood pressure. Through its unique chemical interaction of the impregnated materials in the plaster, it emits a low-frequency vibration to the blood, thus improving its circulation.

SmartPeep has a mission to provide better elderly care with AI, by offering virtual elderly-sitter systems to help caregivers to monitor and respond better to older adults who are at risk, and who need help. They aim to penetrate the huge aging population market in Asia in the next 5 years. The company was co-founded in Oct 2017 by a machine-learning and pattern recognition specialist, a mobile software developer, a product, sales & marketing person, and a camera hardware expert. The team has grown to over 10 members now.

　SmartPeep has received several awards in Singapore and Malaysia, and has been covered by media including The Edge Singapore, Oriental Daily News Malaysia, and KrAsia. SmartPeep has secured more than US$400,000 funds from accelerator and angel investors.

Aware Group was incorporated as a Data and AI company in September 2016. The company bootstrapped from the beginning using services revenue to grow the team and provide funds for developing products. There are now over 20 staff in New Zealand with teams growing in the United States and Singapore.

Aware Group has created deep ties with industry partners such as Microsoft (at the global level), to gain access to large customers across the world. These networks are especially important for Aware Group to understand the industry, but also to build a channel to sell products. Aware Group released its first Software-as-a-Service product, Aware Cognitive Platform (ACP) in 2019 and these networks have been invaluable.

ACP enables customers to rapidly deploy and realise the value of AI in their business. Aware Group have built several ACP Modules to support customer scenarios including (but not limited to) People Counting, Automated Number Plate Recognition and Audio Classification. Aware Group have run a number of pilots of the technology and are going through commercials for production deployments right now.

Our goal is to improve the health and wellbeing of every person by creating products and services that creates the importance of knowing the　kind of environment people live in, how it affects their lives on a daily basis, and guide the actions needed to improve their environment, health and wellbeing.

Motorica is a company with offices in Russia (HQ), China and India focusing on research and development in medicine and robotics. Since its establishment, the company has been developing artificial hand systems and rehabilitation with assistive technologies. Half of the team are R&D staff and medical specialists.
　Motorica challenges the outdated ideas about prosthetic care. The team taught prostheses to communicate with the user, go online, perform voice commands, pay for purchases. In 2018, Motorica launched the development of a rehabilitation platform based on virtual reality and a platform for collecting telemetry via gsm-module in prosthetic devices. Nowadays, people with disabilities become the primary users of the cyber technology market and turn weaknesses into strengths.